Semax is a synthetic heptapeptide (seven amino acids) derived from the ACTH (4-10) fragment — the portion of adrenocorticotropic hormone responsible for cognitive and neurotrophic effects, without the adrenal-stimulating properties of the full ACTH molecule.
The primary mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). BDNF is critical for neuroplasticity — the brain's ability to form new neural connections, consolidate memories, and adapt to new information. Semax has been shown to increase BDNF expression in the hippocampus and prefrontal cortex.
Semax also modulates dopaminergic and serotonergic neurotransmission, enhancing attention, working memory, and motivation without the stimulant-like side effects of amphetamines. It influences the expression of genes involved in immune response within the brain, providing neuroprotective effects.
The peptide is administered intranasally, allowing direct access to the central nervous system via the olfactory pathway — bypassing the blood-brain barrier.
Semax has been extensively researched in Russia, where it holds approved pharmaceutical status, and is gaining attention in Western nootropic and neurology communities.
Cognitive Enhancement: Clinical studies in healthy volunteers demonstrated improvements in attention, short-term memory, and cognitive processing speed. Russian clinical trials used Semax for cognitive decline associated with aging and cerebrovascular disease.
Stroke Recovery: Multiple clinical trials in Russia demonstrated that Semax administered during the acute phase of ischemic stroke improved neurological outcomes and reduced infarct volume. It is approved in Russia as a treatment for stroke and transient ischemic attacks.
BDNF Upregulation: Animal studies confirmed that Semax significantly increases BDNF mRNA expression in the hippocampus and basal forebrain, with effects lasting for up to 24 hours after a single dose.
Neuroprotection: Research has shown that Semax protects neurons against oxidative stress, excitotoxicity, and inflammation — mechanisms involved in neurodegenerative conditions. Studies in optic nerve damage models showed improved nerve fiber survival.
ADHD & Focus: While formal ADHD clinical trials are limited, anecdotal and clinical reports suggest Semax improves attention span and executive function in individuals with attention disorders, likely through its BDNF and dopaminergic effects.
The following protocols are reported from clinical practice. This is not medical advice. Consult a licensed healthcare provider before starting any peptide therapy.
Semax is primarily administered intranasally. Reported clinical protocols include:
Standard Nootropic Protocol: 200–600 mcg intranasally per day, divided into 1–2 doses (morning and early afternoon). Most providers start at 200 mcg and titrate up based on response.
Enhanced Cognitive Protocol: 600–900 mcg per day for periods of high cognitive demand (exams, intensive work). Not recommended for continuous use at this dose.
N-Acetyl Semax (NASA) Variant: A modified version with an acetyl group that enhances stability and potency. Typical dosing is 100–300 mcg intranasally.
Amidate Variant: The most potent form. Dosing is typically 100–200 mcg intranasally due to increased bioavailability.
Cycle Length: 2–4 weeks on, 1–2 weeks off. Some providers allow longer cycles at lower doses (200 mcg/day) with periodic breaks.
Semax has an excellent safety profile based on decades of use in Russia. Commonly reported effects include mild nasal irritation (from intranasal delivery), occasional headache during the first few days, temporary hair shedding (rare, reported with high doses), and mild emotional sensitivity or mood fluctuations.
Semax does not appear to cause the tolerance, dependence, or withdrawal effects associated with traditional stimulants. It does not significantly affect cortisol levels (unlike full ACTH), blood pressure, or heart rate.
Verified suppliers with third-party testing and COA documentation. Use code POWER where applicable.
Semax and Modafinil work through different mechanisms. Modafinil is a wakefulness-promoting agent that affects orexin, dopamine, and histamine systems. Semax primarily works by upregulating BDNF and modulating neurotrophic factors. Semax tends to enhance learning, memory, and neuroplasticity, while Modafinil is more focused on alertness and wakefulness.
Yes, Semax (cognitive enhancer) and Selank (anxiolytic) are frequently stacked. The combination provides focused cognitive enhancement from Semax with the calming, anxiety-reducing effects of Selank — described as "calm focus" by users. They are administered intranasally, typically alternating nostrils.
Intranasal delivery allows Semax to reach the brain directly through the olfactory nerve pathway, bypassing the blood-brain barrier. This provides higher brain bioavailability with smaller doses compared to systemic injection. It also makes administration much simpler and non-invasive.
Yes, Semax is an approved pharmaceutical in Russia, where it has been used clinically since the 1990s for stroke recovery, cognitive decline, peptic ulcers, and optic nerve disease. In the U.S., it is classified as Category 1 (cleared for compounding) but is not FDA-approved as a standalone drug.
Take our 2-minute quiz to get a personalized peptide recommendation based on your goals, experience level, and health priorities.
Take the Peptide Quiz →This content is for informational and educational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease or condition. Always consult with a qualified healthcare provider before starting any peptide therapy or supplement regimen. Peptide protocols described on this page reflect reported clinical practices and published research — not recommendations. Individual results may vary. Read full disclaimer.
Affiliate Disclosure: PeptideOnline.co participates in affiliate programs with suppliers featured on this page. We may earn a commission on qualifying purchases at no additional cost to you. Our editorial content is independent and not influenced by affiliate relationships. Learn more.